Biosystems RapidFinder Shiga Toxin-Producing E. coli
Parameter identifiability evaluation and visualization in large-scale kinetic fashions of biosystems.
BACKGROUND
Kinetic fashions of biochemical methods normally include odd differential equations which have many unknown parameters. A few of these parameters are sometimes virtually unidentifiable, that’s, their values can’t be uniquely decided from the out there knowledge.
Attainable causes are lack of affect on the measured outputs, interdependence amongst parameters, and poor knowledge high quality. Uncorrelated parameters might be seen as the important thing tuning knobs of a predictive mannequin. Due to this fact, earlier than making an attempt to carry out parameter estimation (mannequin calibration) it is very important characterize the subset(s) of identifiable parameters and their interaction. As soon as that is achieved, it’s nonetheless essential to carry out parameter estimation, which poses further challenges.
METHODS
We current a technique that (i) detects high-order relationships amongst parameters, and (ii) visualizes the outcomes to facilitate additional evaluation. We use a collinearity index to quantify the correlation between parameters in a gaggle in a computationally environment friendly method. Then we apply integer optimization to search out the biggest teams of uncorrelated parameters. We additionally use the collinearity index to establish small teams of extremely correlated parameters. The outcomes recordsdata might be visualized utilizing Cytoscape, exhibiting the identifiable and non-identifiable teams of parameters along with the mannequin construction in the identical graph.
RESULTS
Our contributions alleviate the difficulties that seem at totally different levels of the identifiability evaluation and parameter estimation course of. We present easy methods to mix world optimization and regularization methods for calibrating medium and huge scale organic fashions with average computation occasions.
Then we consider the sensible identifiability of the estimated parameters utilizing the proposed methodology. The identifiability evaluation methods are applied as a MATLAB toolbox known as VisId, which is freely out there as open supply from GitHub ( https://github.com/gabora/visid ).
CONCLUSIONS
Our strategy is geared in the direction of scalability. It permits the sensible identifiability evaluation of dynamic fashions of enormous dimension, and accelerates their calibration. The visualization device permits modellers to detect elements which might be problematic and want refinement or reformulation, and offers experimentalists with info that may be useful within the design of recent experiments.
Validation of the Utilized Biosystems RapidFinder Shiga Toxin-Producing E. coli (STEC) Detection Workflow.
The Utilized Biosystems™ RapidFinder™ STEC Detection Workflow (Thermo Fisher Scientific) is a whole protocol for the speedy qualitative detection of Escherichia coli (E. coli) O157:H7 and the “Huge 6” non-O157 Shiga-like toxin-producing E. coli (STEC) serotypes (outlined as serogroups: O26, O45, O103, O111, O121, and O145).
The RapidFinder STEC Detection Workflow makes use of both the automated preparation of PCR-ready DNA utilizing the Utilized Biosystems PrepSEQ™ Nucleic Acid Extraction Package along side the Utilized Biosystems MagMAX™ Specific 96-well magnetic particle processor or the Utilized Biosystems PrepSEQ Speedy Spin equipment for handbook preparation of PCR-ready DNA.
Two separate assays comprise the RapidFinder STEC Detection Workflow, the Utilized Biosystems RapidFinder STEC Screening Assay and the Utilized Biosystems RapidFinder STEC Affirmation Assay. The RapidFinder STEC Screening Assay contains primers and probes to detect the presence of stx1 (Shiga toxin 1), stx2 (Shiga toxin 2), eae (intimin), and E. coli O157 gene targets. The RapidFinder STEC Affirmation Assay contains primers and probes for the “Huge 6″ non-O157 STEC and E. coli O157:H7. Using these two assays in tandem permits a person to detect precisely the presence of the “Huge 6” STECs and E. coli O157:H7. The efficiency of the RapidFinder STEC Detection Workflow was evaluated in a technique comparability research, in inclusivity and exclusivity research, and in a robustness analysis.
The assays had been in comparison with the U.S. Division of Agriculture (USDA), Meals Security and Inspection Service (FSIS) Microbiology Laboratory Guidebook (MLG) 5.09: Detection, Isolation and Identification of Escherichia coli O157:H7 from Meat Merchandise and Carcass and Environmental Sponges for uncooked floor beef (73% lean) and USDA/FSIS-MLG 5B.05: Detection, Isolation and Identification of Escherichia coli non-O157:H7 from Meat Merchandise and Carcass and Environmental Sponges for uncooked beef trim. No statistically important variations had been noticed between the reference methodology and the person or mixed kits forming the candidate assay utilizing both of the DNA preparation kits (handbook or automated extraction). For the inclusivity and exclusivity analysis, the RapidFinder STEC Detection Workflow, comprising each RapidFinder STEC screening and affirmation kits, accurately recognized all 50 goal organism isolates and accurately excluded all 30 nontarget strains for each of the assays evaluated.
The outcomes of those research reveal the sensitivity and selectivity of the RapidFinder STEC Detection Workflow for the detection of E. coli O157:H7 and the “Huge 6” STEC serotypes in each uncooked floor beef and beef trim. The robustness testing demonstrated that minor variations within the methodology parameters didn’t influence the accuracy of the assay and highlighted the significance of following the right incubation temperatures.
Description: Chemokine (C-X-C motif) ligand 7 (CXCL7), also known as NAP-2 or Pro-Platelet basic protein (PPBP), is a human gene. The protein encoded by this gene is a platelet-derived growth factor that belongs to the CXC chemokine family. This growth factor is a potent chemoattractant and activator of neutrophils. It has been shown to stimulate various cellular processes including DNA synthesis, mitosis, glycolysis, intracellular cAMP accumulation, prostaglandin E2 secretion, and synthesis of hyaluronic acid and sulfated glycosaminoglycan. It also stimulates the formation and secretion of plasminogen activator by synovial cells. Furthermore, the protein is an antimicrobial protein with bactericidal and antifungal activity.
Description: Recombinant NAP-2 is a disulfide-linked monomeric protein consisting of 71 amino acid residues and migrates as an approximately 8 kDa protein under non-reducing conditions and reducing conditions in SDS-PAGE. Optimized DNA sequence encoding Human NAP-2 (CXCL7) mature chain was expressed in E. coli.
Description: Recombinant NAP-2 is a disulfide-linked monomeric protein consisting of 71 amino acid residues and migrates as an approximately 8 kDa protein under non-reducing conditions and reducing conditions in SDS-PAGE. Optimized DNA sequence encoding Human NAP-2 (CXCL7) mature chain was expressed in E. coli.
Description: Human Chemokine (C-X-C motif) Ligand 7 (CXCL7), also known as neutrophil activating peptide 2 (NAP-2), is a member of the CXC chemokines containing an ELR domain (Glu-Leu-Arg tripeptide motif). Similar to other ELR domain containing CXC chemokines, such as IL-8 and the GRO proteins, CXCL7 binds CXCR2, chemoattracts and activates neutrophils. CXCL7, Connective Tissue Activating Protein III (CTAPIII) and beta thrombogulin ( beta TG), are proteolytically processed carboxylterminal fragments of platelet basic protein (PBP) which is found in the alphagranules of human platelets. Although CTAPIII, beta TG, and PBP represent amino-terminal extended variants of NAP2 and possess the same CXC chemokine domains, these proteins do not exhibit CXCL7/NAP2 activity. CXCL7 induces cell migration through the G-protein-linked receptor CXCR-2.
Description: Human Chemokine (C-X-C motif) Ligand 7 (CXCL7), also known as neutrophil activating peptide 2 (NAP-2), is a member of the CXC chemokines containing an ELR domain (Glu-Leu-Arg tripeptide motif). Similar to other ELR domain containing CXC chemokines, such as IL-8 and the GRO proteins, CXCL7 binds CXCR2, chemoattracts and activates neutrophils. CXCL7, Connective Tissue Activating Protein III (CTAPIII) and beta thrombogulin ( beta TG), are proteolytically processed carboxylterminal fragments of platelet basic protein (PBP) which is found in the alphagranules of human platelets. Although CTAPIII, beta TG, and PBP represent amino-terminal extended variants of NAP2 and possess the same CXC chemokine domains, these proteins do not exhibit CXCL7/NAP2 activity. CXCL7 induces cell migration through the G-protein-linked receptor CXCR-2.
Description: Chemokine (C-X-C motif) ligand 7 (CXCL7), also known as NAP2 or Pro-Platelet basic protein (PPBP), is a human gene. The protein encoded by this gene is a platelet-derived growth factor that belongs to the CXC chemokine family. This growth factor is a potent chemoattractant and activator of neutrophils. It has been shown to stimulate various cellular processes including DNA synthesis, mitosis, glycolysis, intracellular cAMP accumulation, prostaglandin E2 secretion, and synthesis of hyaluronic acid and sulfated glycosaminoglycan. It also stimulates the formation and secretion of plasminogen activator by synovial cells. Furthermore, the protein is an antimicrobial protein with bactericidal and antifungal activity.
Description: A sandwich ELISA kit for quantitative measurement of Mouse ?TG/PBP/CXCL7/NAP2 (Thromboglobulin, Beta) in samples from Serum, Plasma, Cell supernatant
Description: Enzyme-linked immunosorbent assay kit for quantification of Human CXCL7 in samples from serum, plasma, tissue homogenates and other biological fluids.
Description: For the development of sandwich ELISA kit to measure human CXCL7 in cell culture supernates, cell lysates, tissue homogenates, serum and plasma (heparin, EDTA).
Recombinant Rat Neutrophil Activating Protein-2 (CXCL7)
Description: A sandwich ELISA kit for quantitative measurement of Rat ?TG/PBP/CXCL7/NAP2 (Thromboglobulin, Beta) in samples from Serum, Plasma, Cell supernatant
ELISA kit for Human ?TG/PBP/CXCL7/NAP2 (Thromboglobulin, Beta)
Description: A polyclonal antibody raised in Rabbit that recognizes and binds to Human (Mouse) Cxcl12 . This antibody is tested and proven to work in the following applications:
NAP-2 Neutrophil Activating Protein-2 Rat Recombinant Protein (CXCL7)
Description: NAP-2 Rat Recombinant produced in E.coli is a single, non-glycosylated polypeptide chain containing 62 amino acids and having a molecular mass of 6.8kDa.;The NAP 2 is purified by proprietary chromatographic techniques.
NAP-2 Neutrophil Activating Protein-2 Human Recombinant Protein (CXCL7)
Description: Neutrophil Activating Protein-2 Human Recombinant produced in E.Coli is a non-glycosylated, Polypeptide chain containing 70 amino acids and having a molecular mass of 7609 Dalton. ;The NAP-2 is purified by proprietary chromatographic techniques.
Description: The kit is a sandwich enzyme immunoassay for in vitro quantitative measurement of IP-10/CXCL10 in Mouse serum, plasma and other biological fluids
Description: Enzyme-linked immunosorbent assay kit for quantification of Mouse CXCL16 in samples from serum, plasma, tissue homogenates and other biological fluids.
Description: NAP 2 Human Recombinant produced in E.coli is a single, non-glycosylated polypeptide chain containing 95 amino acids (35-128) and having a molecular mass of 10.3 kDa.;The NAP 2 is purified by proprietary chromatographic techniques.
Description: The C-X-C motif chemokine CXCL12 binds to one single chemokine receptor, CXCR4, to mediate cell-type specific physiological processes, including cellular migration, survival, and apoptosis. CXCL12 and its receptor CXCR4 play a role in many different diseases, including cancer, HIV, and rheumatoid arthritis. Mouse CXCL12 Recombinant Protein is purified CXCL12 produced in yeast.
Description: The ELR-negative CXC chemokine CXCL10 (IP-10) has been attributed to several roles, such as chemoattraction for monocytes/macrophages, T cells, NK cells, and dendritic cells, promotion of T cell adhesion to endothelial cells, antitumor activity, and inhibition of bone marrow colony formation and angiogenesis. Mouse CXCL10 Recombinant Protein is purified CXCL10 (IP-10) produced in yeast.
Description: Enzyme-linked immunosorbent assay kit for quantification of Mouse CXCL10/IP-10 in samples from serum, plasma, tissue homogenates and other biological fluids.
Description: Enzyme-linked immunosorbent assay kit for quantification of Mouse CXCL1 in samples from serum, plasma, tissue homogenates and other biological fluids.
Description: Enzyme-linked immunosorbent assay kit for quantification of Mouse CXCL9 in samples from serum, plasma, tissue homogenates and other biological fluids.
Description: Enzyme-linked immunosorbent assay kit for quantification of Mouse CXCL3 in samples from serum, plasma, tissue homogenates and other biological fluids.
Description: Enzyme-linked immunosorbent assay kit for quantification of Mouse CXCL4/PF4 in samples from serum, plasma, tissue homogenates and other biological fluids.
Validation of the Utilized Biosystems 7500 Quick Instrument for Detection of Listeria monocytogenes with the SureTect Listeria monocytogenes PCR Assay.
In 2013, the Thermo Scientific™ SureTect™ Listeria monocytogenes Actual-Time PCR Assay was licensed by the AOAC Analysis Institute (RI) Efficiency Examined Strategies(SM) program as a speedy methodology for the detection of L. monocytogenes from a variety of meals matrixes and floor samples.
This report particulars the tactic modification research undertaken to increase the evaluation of this PCR assay to the Utilized Biosystems™ 7500 Quick PCR Instrument and Utilized Biosystems RapidFinder™ Specific 2.zero software permitting the usage of the SureTect assay on a 96 effectively format PCR cycler along with the present workflow, which makes use of the 24 effectively Thermo Scientific PikoReal™ PCR Instrument and Thermo Scientific SureTect software program.
As a result of this research was deemed by AOAC-RI to be a degree 2 methodology modification research, a consultant vary of meals matrixes overlaying uncooked floor turkey, 2% fats pasteurized milk, and bagged lettuce in addition to chrome steel floor samples had been analyzed with the Utilized Biosystems 7500 Quick PCR Instrument and RapidFinder Specific 2.zero software program.
All testing was carried out compared to the reference methodology detailed in Worldwide Group for Standardization (ISO) 6579:2002. No important distinction by likelihood of detection statistical evaluation was discovered between the SureTect Listeria monocytogenes PCR Assay or the ISO reference methodology strategies for any of the matrixes analyzed throughout the research.
Validation of the Utilized Biosystems 7500 Quick Instrument for the Detection of Salmonellae with SureTect Salmonella Species PCR Package.
The Thermo Scientific SureTect™ Salmonella species real-time PCR assay is a speedy various methodology designed for the detection of salmonellae in a variety of meals, animal feeds, and production-environment samples. The assay has beforehand been validated in accordance with the AOAC Analysis Institute Efficiency Examined Strategies(SM) program utilizing Thermo Scientific PikoReal PCR cycler and Thermo Scientific SureTect Software program Efficiency Examined Methodology 051303).
This report particulars the method-modification research carried out to validate an up to date assay format, using a diminished goal probe focus and an extension of the PCR cycler platform to allow the usage of the equipment with a Utilized Biosystems 7500 Quick PCR cycler and Utilized Biosystems RapidFinder™ Specific 2.zero software program.
Throughout this validation research, a matrix research was carried out on a subset of the tactic’s claimed matrixes, evaluating the efficiency of the modified SureTect Salmonella species equipment (a diminished goal probe focus with a 7500 Quick platform) to the reference methodology detailed in ISO 6579:2002.
No important distinction by likelihood of detection statistical evaluation was discovered between SureTect or Worldwide Group for Standardization strategies for any of the matrixes analyzed throughout the research. Inclusivity and exclusivity research utilizing the modified methodology demonstrated correct outcomes for the 117 Salmonella and 36 non-Salmonella strains examined. A number of manufacturing plenty of the newly formatted equipment had been evaluated and located to be in step with the present assay. Robustness research confirmed that the change to the equipment had no influence on the assay’s efficiency when alterations had been made to methodology parameters having the best potential influence on assay efficiency.
Description: A polyclonal antibody for IGF-1 from Human | Mouse. The antibody is produced in rabbit after immunization with human synthetic peptide from the mid-protein of Human IGF-1. The Antibody is tested and validated for WB, ICC/IF, IHC assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100); IHC (1:50). This IGF-1 antibody is conjugated to Alkaline Phosphatase.
Description: A polyclonal antibody for IGF-1 from Human | Mouse. The antibody is produced in rabbit after immunization with human synthetic peptide from the mid-protein of Human IGF-1. The Antibody is tested and validated for WB, ICC/IF, IHC assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100); IHC (1:50). This IGF-1 antibody is conjugated to Dylight 350.
Description: A polyclonal antibody for IGF-1 from Human | Mouse. The antibody is produced in rabbit after immunization with human synthetic peptide from the mid-protein of Human IGF-1. The Antibody is tested and validated for WB, ICC/IF, IHC assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100); IHC (1:50). This IGF-1 antibody is conjugated to Dylight 405.
Description: A polyclonal antibody for IGF-1 from Human | Mouse. The antibody is produced in rabbit after immunization with human synthetic peptide from the mid-protein of Human IGF-1. The Antibody is tested and validated for WB, ICC/IF, IHC assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100); IHC (1:50). This IGF-1 antibody is conjugated to Dylight 488.
Description: A polyclonal antibody for IGF-1 from Human | Mouse. The antibody is produced in rabbit after immunization with human synthetic peptide from the mid-protein of Human IGF-1. The Antibody is tested and validated for WB, ICC/IF, IHC assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100); IHC (1:50). This IGF-1 antibody is unconjugated.
Description: A polyclonal antibody for IGF-1 from Human | Mouse. The antibody is produced in rabbit after immunization with human synthetic peptide from the mid-protein of Human IGF-1. The Antibody is tested and validated for WB, ICC/IF, IHC assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100); IHC (1:50). This IGF-1 antibody is conjugated to ATTO 390.
Description: A polyclonal antibody for IGF-1 from Human | Mouse. The antibody is produced in rabbit after immunization with human synthetic peptide from the mid-protein of Human IGF-1. The Antibody is tested and validated for WB, ICC/IF, IHC assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100); IHC (1:50). This IGF-1 antibody is conjugated to ATTO 488.
Description: A polyclonal antibody for IGF-1 from Human | Mouse. The antibody is produced in rabbit after immunization with human synthetic peptide from the mid-protein of Human IGF-1. The Antibody is tested and validated for WB, ICC/IF, IHC assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100); IHC (1:50). This IGF-1 antibody is conjugated to ATTO 565.
Description: A polyclonal antibody for IGF-1 from Human | Mouse. The antibody is produced in rabbit after immunization with human synthetic peptide from the mid-protein of Human IGF-1. The Antibody is tested and validated for WB, ICC/IF, IHC assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100); IHC (1:50). This IGF-1 antibody is conjugated to ATTO 594.
Description: A polyclonal antibody for IGF-1 from Human | Mouse. The antibody is produced in rabbit after immunization with human synthetic peptide from the mid-protein of Human IGF-1. The Antibody is tested and validated for WB, ICC/IF, IHC assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100); IHC (1:50). This IGF-1 antibody is conjugated to ATTO 633.
Description: A polyclonal antibody for IGF-1 from Human | Mouse. The antibody is produced in rabbit after immunization with human synthetic peptide from the mid-protein of Human IGF-1. The Antibody is tested and validated for WB, ICC/IF, IHC assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100); IHC (1:50). This IGF-1 antibody is conjugated to ATTO 655.
Description: A polyclonal antibody for IGF-1 from Human | Mouse. The antibody is produced in rabbit after immunization with human synthetic peptide from the mid-protein of Human IGF-1. The Antibody is tested and validated for WB, ICC/IF, IHC assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100); IHC (1:50). This IGF-1 antibody is conjugated to ATTO 680.
Description: A polyclonal antibody for IGF-1 from Human | Mouse. The antibody is produced in rabbit after immunization with human synthetic peptide from the mid-protein of Human IGF-1. The Antibody is tested and validated for WB, ICC/IF, IHC assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100); IHC (1:50). This IGF-1 antibody is conjugated to ATTO 700.
Description: A polyclonal antibody for IGF-1 from Human | Mouse. The antibody is produced in rabbit after immunization with human synthetic peptide from the mid-protein of Human IGF-1. The Antibody is tested and validated for WB, ICC/IF, IHC assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100); IHC (1:50). This IGF-1 antibody is conjugated to APC .
Description: A polyclonal antibody for IGF-1 from Human | Mouse. The antibody is produced in rabbit after immunization with human synthetic peptide from the mid-protein of Human IGF-1. The Antibody is tested and validated for WB, ICC/IF, IHC assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100); IHC (1:50). This IGF-1 antibody is conjugated to APC/Cy7.
Description: A polyclonal antibody for IGF-1 from Human | Mouse. The antibody is produced in rabbit after immunization with human synthetic peptide from the mid-protein of Human IGF-1. The Antibody is tested and validated for WB, ICC/IF, IHC assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100); IHC (1:50). This IGF-1 antibody is conjugated to Biotin.
Description: A polyclonal antibody for IGF-1 from Human | Mouse. The antibody is produced in rabbit after immunization with human synthetic peptide from the mid-protein of Human IGF-1. The Antibody is tested and validated for WB, ICC/IF, IHC assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100); IHC (1:50). This IGF-1 antibody is conjugated to Dylight 594.
Description: A polyclonal antibody for IGF-1 from Human | Mouse. The antibody is produced in rabbit after immunization with human synthetic peptide from the mid-protein of Human IGF-1. The Antibody is tested and validated for WB, ICC/IF, IHC assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100); IHC (1:50). This IGF-1 antibody is conjugated to Dylight 633.
Description: A polyclonal antibody for IGF-1 from Human | Mouse. The antibody is produced in rabbit after immunization with human synthetic peptide from the mid-protein of Human IGF-1. The Antibody is tested and validated for WB, ICC/IF, IHC assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100); IHC (1:50). This IGF-1 antibody is conjugated to FITC.
Description: A polyclonal antibody for IGF-1 from Human | Mouse. The antibody is produced in rabbit after immunization with human synthetic peptide from the mid-protein of Human IGF-1. The Antibody is tested and validated for WB, ICC/IF, IHC assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100); IHC (1:50). This IGF-1 antibody is conjugated to HRP.
Description: A polyclonal antibody for IGF-1 from Human | Mouse. The antibody is produced in rabbit after immunization with human synthetic peptide from the mid-protein of Human IGF-1. The Antibody is tested and validated for WB, ICC/IF, IHC assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100); IHC (1:50). This IGF-1 antibody is conjugated to PE/ATTO 594.
Description: A polyclonal antibody for IGF-1 from Human | Mouse. The antibody is produced in rabbit after immunization with human synthetic peptide from the mid-protein of Human IGF-1. The Antibody is tested and validated for WB, ICC/IF, IHC assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100); IHC (1:50). This IGF-1 antibody is conjugated to PerCP.
Description: A polyclonal antibody for IGF-1 from Human | Mouse. The antibody is produced in rabbit after immunization with human synthetic peptide from the mid-protein of Human IGF-1. The Antibody is tested and validated for WB, ICC/IF, IHC assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100); IHC (1:50). This IGF-1 antibody is conjugated to RPE .
Description: A polyclonal antibody for IGF-1 from Human | Mouse. The antibody is produced in rabbit after immunization with human synthetic peptide from the mid-protein of Human IGF-1. The Antibody is tested and validated for WB, ICC/IF, IHC assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100); IHC (1:50). This IGF-1 antibody is conjugated to Streptavidin.
Description: A polyclonal antibody for IGF-1 from Human | Mouse. The antibody is produced in rabbit after immunization with human synthetic peptide from the mid-protein of Human IGF-1. The Antibody is tested and validated for WB, ICC/IF, IHC assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100); IHC (1:50). This IGF-1 antibody is unconjugated.
Description: Insulin-like growth factor I (IGF-1) is a polypeptide endocrine hormone structurally similar to insulin and is mainly produced in the liver when stimulated by growth hormone. IGF-1 is a growth factor that stimulates the proliferation of various cell types including muscle, bone, and cartilage tissue
Description: Insulin-like growth factor I (IGF-1) is a polypeptide endocrine hormone structurally similar to insulin and is mainly produced in the liver when stimulated by growth hormone. IGF-1 is a growth factor that stimulates the proliferation of various cell types including muscle, bone, and cartilage tissue
Description: IGF-BPs controls the distribution, function and activity of IGFs in various cell tissues and body fluids. Currently there are seven named IGF-BPs that form high affinity complexes with both IGF-I and IGF-II. IGF-BP1 is a 25.4 kDa cysteine-rich secreted protein expressed in liver, deciduas, and kidneys and is the most abundant IGF-BP in amniotic fluid. Levels of IGF-BP1 in serum are lowest after food. IGF-BP1 binds to both IGF-I and IGF-II with equal affinity. Phosphorylated IGF-BP1 hinders IGF actions, where as nonphosphorylated IGF-BP1 is stimulatory. Recombinant human IGF-BP1 is a 25.4 kDa protein consisting of 235 amino acid residues (Isoform A).
Description: IGF-BP3 is a 30 kDa cysteine-rich secreted protein. It is the major IGF binding protein present in the plasma of human and animals and it is also found in α-granules of platelets. In addition to its ability to modulate the activity of IGF-I and IGF-II, IGF-BP3 exerts inhibitory effects on follicle stimulating hormone (FSH) activity. Decreased plasma levels of IGF-BP3 often results in dwarfism, whereas elevated levels of IGF-BP3 may lead to acromegaly. The expression of IGF-BP3 in fibroblasts is stimulated by mitogenic growth factors such as Bombesin, Vasopressin, PDGF, and EGF. Recombinant human IGF-BP3 is a 28.8 kDa protein consisting of 264 amino acid residues.
Description: IGF-BPs controls the distribution, function and activity of IGFs in various cell tissues and body fluids. Currently there are seven named IGF-BPs that form high affinity complexes with both IGF-I and IGF-II. IGF-BP2 is a cysteine-rich secreted protein produced by bone cells, and is most abundant in the brain. IGF-BP2 has been shown to inhibit IGF-II action in human breast and ovarian carcinoma cells. Recombinant human IGF-BP2 is a 31.5 kDa protein consisting of 289 amino acid residues including the IGF-BP domain and thyroglobulin type-I domain.
*Manufactured using (BTI-Tn-5B1-4) cells under license from the Boyce Thompson Institute for Plant Research, Inc.
Description: IGF-BPs controls the distribution, function and activity of IGFs in various cell tissues and body fluids. IGF-BP6 is produced by bone cells and is the major IGF-BP present in cerebrospinal fluid, and specifically inhibits IGF-II actions. IGF-BP6 has been shown to inhibit IGF-II-dependent cancers such as neuroblastoma, colon cancer and rhabdomyosarcoma. Recombinant human IGF-BP6 has a calculated mass of 22.6 kDa and consists of 213 amino acid residues including the IGF-BP domain and thyroglobulin type-I domain. IGF-BP6 migrates at an apparent molecular weight of approximately 23.0-30.0 kDa by SDS-PAGE analysis under non-reducing conditions.
*Manufactured using (BTI-Tn-5B1-4) cells under license from the Boyce Thompson Institute for Plant Research, Inc.
Description: IGF-BPs controls the distribution, function and activity of IGFs in various cell tissues and body fluids. Currently there are seven named IGF-BPs that form high affinity complexes with both IGF-I and IGF-II. IGF-BP5 is a 28.6 kDa cysteine-rich secreted protein produced by vascular smooth muscle cells. It is the major IGF-binding protein present in bone tissue and helps potentiate the action of IGF-I on smooth muscle cells, fibroblasts or osteoblasts. Data shows that IGFBP-5 acts as a growth inhibitor and pro-apoptotic agent in breast cancer cells. IGFBP-5 overexpressing mice show an increase in neonatal mortality, reduced female fertility, whole-body growth inhibition and retarded muscle development. Recombinant human IGF-BP5 is a 28.6 kDa protein consisting of 253 amino acid residues.
Description: IGF-BPs controls the distribution, function and activity of IGFs in various cell tissues and body fluids. Currently there are seven named IGF-BPs that form high affinity complexes with both IGF-I and IGF-II. IGF-BP7 is expressed in a wide range of normal human tissues and it generally shows reduced expression in cancer cell lines of prostate, breast, colon, and lung origin. It plays a role in skeletal myogenesis by binding to IGF in a manner that inhibits IGF induced differentiation of skeletal myoblasts, without affecting IGF induced proliferation. Additionally, IGF-BP7 suppresses growth and colony formation of prostate and breast cancer cell lines through an IGF independent mechanism, which causes a delay in the G1 phase of the cell cycle, and increased apoptosis. Recombinant human IGF-BP7 is a 26.4 kDa protein consisting of 256 amino acid residues.
Description: A polyclonal antibody raised in Rabbit that recognizes and binds to Human Anti-Rat IGF-1 . This antibody is tested and proven to work in the following applications:
Description: Insulin-like Growth Factor-II (IGF-II) is a polypeptide endocrine hormone structurally similar to insulin and belongs to insulin-like growth factor family.
Description: Insulin-like Growth Factor-II (IGF-II) is a polypeptide endocrine hormone structurally similar to insulin and belongs to insulin-like growth factor family.
Description: Insulin-like Growth Factor-II (IGF-II) is a polypeptide endocrine hormone structurally similar to insulin and belongs to insulin-like growth factor family.
